Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats

Neuropsychopharmacology

Volumn 29, Issue 4, 2004, Pages 694-704

  Thompson, Murray R ^a   Li, Kong N ^b   Clemens, Kelly J ^a   Gurtman, Clint G ^a   Hunt, Glenn E ^a   Cornish, Jennifer L ^a   McGregor, Iain S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

Author keywords

5 HIAA; 5 HT; Antidepressant; Anxiety; Depression; Ecstasy; Fluoxetine; MDMA; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; FLUOXETINE; NORFLUOXETINE; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BODY TEMPERATURE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG EFFECT; EMERGENCE TEST; FLUID INTAKE; FORCED SWIMMING TEST; IMMOBILIZATION; LABORATORY TEST; LIMBIC CORTEX; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT; SOCIAL INTERACTION; SOCIAL INTERACTION TEST; WEIGHT REDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; BODY FLUIDS; BODY TEMPERATURE; BODY WEIGHT; BRAIN; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION; DRINKING; DRUG INTERACTIONS; FLUOXETINE; IMMOBILIZATION; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; NEUROTRANSMITTER AGENTS; PSYCHOMOTOR PERFORMANCE; RATS; RATS, WISTAR; REACTION TIME; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SWIMMING;

EID: 1642488880     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300347     Document Type: Article

References (58)

1. 3H]paroxetine-labeled serotonin uptake sites. J Pharm Exp Ther 242: 911-916.
2. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG et al (1999). Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19: 10494-10501.
3. Berton O, Durand M, Aguerre S, Mormede P, Chaouloff F (1999). Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain. Neuroscience 92: 327-341.
4. Blokland A, Lieben C, Deutz NEP (2002). Anxiogenic and depressive-like effects, but no cognitive deficits, after repeated moderate tryptophan depletion in the rat. J Psychopharmacol 16: 39-49.
5. Boot BP, McGregor IS, Hall W (2000). MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 355: 1818-1821.
6. Bull EJ, Hutson PH, Fone KC (2003). Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT(2C) receptor responsivity. Neuropharmacology 44: 439-448.
7. Caccia S, Bizzi A, Coltro G, Fracasso C, Frittoli E, Mennini T et al (1992a). Anorectic activity of fluoxetine and norfluoxetine in rats: relationship between brain concentrations and in-vitro potencies on monoaminergic mechanisms. J Pharm Pharmacol 44: 250-254.
8. Caccia S, Cappi M, Fracasso C, Garattini S (1990). Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 100: 509-514.
9. Caccia S, Confalonieri S, Bergami A, Fracasso C, Anelli M, Garattini S (1997). Neuropharmacological effects of low and high doses of repeated oral dexfenfluramine in rats: a comparison with fluoxetine. Pharmacol Biochem Behav 57: 851-856.
10. Caccia S, Fracasso C, Garattini S, Guiso G, Sarati S (1992b). Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology 31: 343-347.
11. Cole JC, Sumnall HR, Grob C (2002). Sorted: ecstasy facts and fiction. Psychologist 15: 464-467.
12. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987). Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharm Exp Ther 241: 338-345.
13. Connor TJ, Kelliher P, Shen Y, Harkin A, Kelly JP, Leonard BE (2000). Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacol Biochem Behav 65: 591-597.
14. Contreras CM, Rodriguez-Landa JF, Gutierrez-Garcia AG, Bernal-Morales B (2001). The lowest effective dose of fluoxetine in the forced swim test significantly affects the firing rate of lateral septal nucleus neurones in the rat. J Psychopharmacol 15: 231-236.
15. Cryan JF, Markou A, Lucki I (2002). Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245.
16. Detke MJ, Johnson J, Lucki I (1997). Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 5: 107-112.
17. Detke MJ, Lucki I (1996). Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav Brain Res 73: 43-46.
18. Durand M, Berton O, Aguerre S, Edno L, Combourieu I, Mormede P et al (1999). Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis axis in SHR and WKY rats. Neuropharmacology 38: 893-907.
19. File SE, Hyde JR (1978). Can social interaction be used to measure anxiety? Br J Pharmacol 62: 19-24.
20. File SE, Ouagazzal AM, Gonzalez LE, Overstreet DH (1999). Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT1A receptor function. Pharmacol Biochem Behav 62: 695-701.
21. Fone KCF, Beckett SRG, Topham IA, Swettenham J, Ball M, Maddocks L (2002). Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology 159: 437-444.
22. Gamma A, Buck A, Berthold T, Hell D, Vollenweider FX (2000). 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by. Neuropsychopharmacol 23: 388-395.
23. Goudie AJ, Thornton EW, Wheeler TJ (1976). Effects of Lilly 110140, a specific inhibitor of 5-hydroxytryptamine uptake, on food intake and on 5-hydroxytryptophan-induced anorexia. Evidence for serotoninergic inhibition of feeding. J Pharm Pharmacol 28: 318-320.
24. Green AR, Cross AJ, Goodwin GM (1995). Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology (Berl) 119: 247-260.
25. Griebel G, Cohen C, Perrault G, Sanger DJ (1999). Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats. Physiol Behav 67: 315-320.
26. Gurtman CG, Morley KC, Li KM, Hunt GE, McGregor IS (2002). Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonergic depletion. Eur J Pharmacol 446: 89-96.
27. 3H] imipramine recognition sites in rat brain by chronic treatment with antidepressants. Eur J Pharmacol 138: 159-168.
28. Jones N, King SM, Duxon MS (2002). Further evidence for the predictive validity of the unstable elevated exposed plus-maze, a behavioural model of extreme anxiety in rats: differential effects of fluoxetine and chlordiazepoxide. Behav Pharmacol 13: 525-535.
29. Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, Seiden LS (1996). Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: radioligand binding and autoradiography studies. J Pharm Exp Ther 276: 855-865.
30. Lightowler S, Kennett GA, Williamson IJ, Blackburn TP, Tulloch IF (1994). Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49: 281-285.
31. MacInnes N, Handley SL, Harding GF (2001). Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 15: 181-186.
32. Malberg JE, Seiden LS (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18: 5086-5094.
33. McGregor IS, Clemens KC, Van der Plasse G, Hunt GE, Chen F, Lawrence AJ (2003a). Increased anxiety three months after brief MDMA ('Ecstasy') treatment in rats: association with altered 5-HT receptor and transporter density. Neuropsychopharmacology 28: 1472-1484.
34. McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, Li KM et al (2003b). Increased anxiety and "depressive" symptoms months after MDMA ('Ecstasy') in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology 168: 465-474.
35. McGuire P (2000). Long term psychiatric and cognitive effects of MDMA use. Toxicol Lett 112-113: 153-156.
36. Minor TR, Dess NK, Ben-David E, Chang WC (1994). Individual differences in vulnerability to inescapable shock in rats. J Exp Psychol Anim Behav Process 20: 402-412.
37. Morgan MJ (2000). Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152: 230-248.
38. Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS (2001). Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ('ecstasy'). Eur J Pharmacol 433: 91-99.
39. Muck-Seler D, Jevric-Causevic A, Diksic M (1996). Influence of fluoxetine on regional serotonin synthesis in the rat brain. J Neurochem 67: 2434-2442.
40. O'Shea E, Granados R, Esteban B, Colado MI, Green AR (1998). The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (ecstasy). Neuropharmacology 37: 919-926.
41. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 147: 162-167.
42. Pare WP, Tejani-Butt S, Kluczynski J (2001). The emergence test: effects of psychotropic drugs on neophobic disposition in Wistar Kyoto (WKY) and Sprague Dawley rats. Prog Neuropsychopharmacol Biol Psychiatry 25: 1615-1628.
43. Parrott AC (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16: 557-577.
44. Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J (2002). Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 17: 309-312.
45. Parrott AC, Sisk E, Turner JJD (2000). Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend 60: 105-110.
46. Porsolt RD, Anton G, Blavet N, Jalfre M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379-391.
47. Prendergast MA, Hendricks SE, Yells DP, Balogh S (1996). Conditioned taste aversion induced by fluoxetine. Physiol Behav 60: 311-315.
48. Ricaurte GA, McCann UD, Szabo Z, Scheffel U (2000). Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol Lett 112: 143-146.
49. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R (1998). MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 52: 85-90.
50. Silva RC, Brandao ML (2000). Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis. Pharmacol Biochem Behav 65: 209-216.
51. Stein JM, Wayner MJ, Kantak KM, Adler-Stein RL (1978). Synergistic action of p-chloroamphetamine and fluoxetine on food and water consumption patterns in the rat. Pharmacol Biochem Behav 9: 677-685.
52. Tejani-Butt S, Kluczynski J, Pare WP (2003). Strain-dependent modification of behavior following antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 27: 7-14.
53. To CT, Anheuer ZE, Bagdy G (1999). Effects of acute and chronic fluoxetine treatment of CRH-induced anxiety. Neuroreport 10: 553-555.
54. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999). Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105-115.
55. Vaswani M, Linda FK, Ramesh S (2003). Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27: 85-102.
56. Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M et al (2001). Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 153: 196-202.
57. Wareing M, Fisk JE, Murphy PN (2000). Working memory deficits in current and previous users of MDMA ('Ecstasy'). Br J Psychol 91: 181-188.
58. Wong DT, Bymaster FP, Engleman EA (1995). Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57: 411-441.